Wound Infection Clinical Trial
Official title:
Azithromycin-based Extended-spectrum Prophylaxis in Scheduled Cesarean Deliveries
Cesarean deliveries are the most common surgical procedure performed in the United States. A significant decrease in cesarean delivery associated maternal morbidity has been achieved with preoperative prophylactic single-dose cephalosporin, widely used before skin incision. Also, on laboring patients and/or with rupture of membranes, several studies suggest that adding azithromycin to standard cephalosporin prophylaxis is cost-effective and reduces overall rates of endometritis, wound infection, readmission, use of antibiotics and serious maternal events. Azithromycin has effective coverage against Ureaplasma, associated with increased rates of endometritis. Although two-drug regimen has been suggested for laboring and/or patients that undergo cesarean delivery, no studies have investigated the potential benefits of two-drug regimen in non-laboring patients.
Status | Recruiting |
Enrollment | 800 |
Est. completion date | November 30, 2020 |
Est. primary completion date | September 30, 2019 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Pregnant women 18 years or older - Women undergoing primary or repeat cesarean delivery - Singleton gestation - Gestational age greater than 34 weeks - Pregnant patients undergoing scheduled cesarean delivery - Intact membranes - Non-laboring - Signed informed consent Exclusion Criteria: - Maternal age < 18 years - Multi-fetal gestation - Known allergy to cephalosporin or azithromycin - Patient unwilling or unable to provide consent - Diagnosis of rupture of membranes - Intraamniotic infection, or any other active bacterial infection (e.g. pyelonephritis, pneumonia, abscess) at time of randomization. - Immunocompromising medical conditions: HIV positive with CD4 count below 200, chronic steroid use, current diagnosis of cancer and/or chemotherapy age use - Emergent cesarean precluding consent or availability of study medication - Need for hysterectomy at time of delivery - Use of antibiotic in the 72 hours prior to admission, with exception to patient receiving antibiotics for GBS - Inability to contact patient on postpartum period. |
Country | Name | City | State |
---|---|---|---|
United States | Jersey City Medical Center | Jersey City | New Jersey |
Lead Sponsor | Collaborator |
---|---|
RWJ Barnabas Health at Jersey City Medical Center |
United States,
American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 120: Use of prophylactic antibiotics in labor and delivery. Obstet Gynecol. 2011 Jun;117(6):1472-83. doi: 10.1097/AOG.0b013e3182238c31. — View Citation
Andrews WW, Hauth JC, Cliver SP, Savage K, Goldenberg RL. Randomized clinical trial of extended spectrum antibiotic prophylaxis with coverage for Ureaplasma urealyticum to reduce post-cesarean delivery endometritis. Obstet Gynecol. 2003 Jun;101(6):1183-9. — View Citation
Andrews WW, Shah SR, Goldenberg RL, Cliver SP, Hauth JC, Cassell GH. Association of post-cesarean delivery endometritis with colonization of the chorioamnion by Ureaplasma urealyticum. Obstet Gynecol. 1995 Apr;85(4):509-14. — View Citation
Boggess KA, Tita A, Jauk V, Saade G, Longo S, Clark EA, Esplin S, Cleary K, Wapner R, Letson K, Owens M, Blackwell S, Beamon C, Szychowski JM, Andrews W; Cesarean Section Optimal Antibiotic Prophylaxis Trial Consortium. Risk Factors for Postcesarean Maternal Infection in a Trial of Extended-Spectrum Antibiotic Prophylaxis. Obstet Gynecol. 2017 Mar;129(3):481-485. doi: 10.1097/AOG.0000000000001899. — View Citation
Harper LM, Kilgore M, Szychowski JM, Andrews WW, Tita ATN. Economic Evaluation of Adjunctive Azithromycin Prophylaxis for Cesarean Delivery. Obstet Gynecol. 2017 Aug;130(2):328-334. doi: 10.1097/AOG.0000000000002129. — View Citation
Skeith AE, Niu B, Valent AM, Tuuli MG, Caughey AB. Adding Azithromycin to Cephalosporin for Cesarean Delivery Infection Prophylaxis: A Cost-Effectiveness Analysis. Obstet Gynecol. 2017 Dec;130(6):1279-1284. doi: 10.1097/AOG.0000000000002333. — View Citation
Smaill FM, Grivell RM. Antibiotic prophylaxis versus no prophylaxis for preventing infection after cesarean section. Cochrane Database Syst Rev. 2014 Oct 28;(10):CD007482. doi: 10.1002/14651858.CD007482.pub3. Review. — View Citation
Smith C, Egunsola O, Choonara I, Kotecha S, Jacqz-Aigrain E, Sammons H. Use and safety of azithromycin in neonates: a systematic review. BMJ Open. 2015 Dec 9;5(12):e008194. doi: 10.1136/bmjopen-2015-008194. Review. — View Citation
Sutton AL, Acosta EP, Larson KB, Kerstner-Wood CD, Tita AT, Biggio JR. Perinatal pharmacokinetics of azithromycin for cesarean prophylaxis. Am J Obstet Gynecol. 2015 Jun;212(6):812.e1-6. doi: 10.1016/j.ajog.2015.01.015. Epub 2015 Jan 13. — View Citation
Tita AT, Hauth JC, Grimes A, Owen J, Stamm AM, Andrews WW. Decreasing incidence of postcesarean endometritis with extended-spectrum antibiotic prophylaxis. Obstet Gynecol. 2008 Jan;111(1):51-6. doi: 10.1097/01.AOG.0000295868.43851.39. — View Citation
Tita AT, Rouse DJ, Blackwell S, Saade GR, Spong CY, Andrews WW. Emerging concepts in antibiotic prophylaxis for cesarean delivery: a systematic review. Obstet Gynecol. 2009 Mar;113(3):675-82. doi: 10.1097/AOG.0b013e318197c3b6. Review. — View Citation
Tita AT, Szychowski JM, Boggess K, Saade G, Longo S, Clark E, Esplin S, Cleary K, Wapner R, Letson K, Owens M, Abramovici A, Ambalavanan N, Cutter G, Andrews W; C/SOAP Trial Consortium. Adjunctive Azithromycin Prophylaxis for Cesarean Delivery. N Engl J Med. 2016 Sep 29;375(13):1231-41. doi: 10.1056/NEJMoa1602044. — View Citation
* Note: There are 12 references in all — Click here to view all references
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Rates of Neonatal Intensive Care Unit (NICU) Admission | Neonatal Intensive Care Unit (NICU) Admission rather than prematurity | Up to 6 weeks after delivery | |
Other | Rates of Neonatal Readmission | Hospital readmission within 6 weeks of birth | Up to 6 weeks after delivery | |
Primary | Rates of Endometritis | Presence of at least two of the following signs with no other recognized cause: fever (temperature of at least 38°C [100.4°F]), abdominal pain, uterine tenderness, or purulent drainage from the uterus. | Up to 6 weeks after delivery | |
Primary | Rates of Wound Infection | Presence of either superficial or deep incisional surgical-site infection characterized by cellulitis or erythema and induration around the incision or purulent discharge from the incision site with or without fever and included necrotizing fasciitis. Wound hematoma, seroma, abscess or breakdown alone in the absence of the preceding signs did not constitute infection. | Up to 6 weeks after delivery | |
Secondary | Rates of Maternal Fever | Temperature equal or greater than 100.4F | Up to 6 weeks after delivery | |
Secondary | Rates of Maternal Postpartum Readmission or Unscheduled Visit | Admission to hospital or unscheduled appointment in additional to regular 1-week and 6-week postpartum visit | Up to 6 weeks after delivery | |
Secondary | Rates of Postpartum Antibiotic Use | Antibiotic use for any reason including other infections such as UTI and sepsis. | Up to 6 weeks after delivery | |
Secondary | Rates of Serious Adverse Events | MICU admission, thromboembolic events, sepsis, maternal death | Up to 6 weeks after delivery |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02905955 -
Vacuumtherapy After Venous Hybrid Procedures
|
Phase 4 | |
Not yet recruiting |
NCT02868372 -
Swabbing of Subcutaneous Tissues of Cesarean Section Wounds With Povidone Iodine
|
N/A | |
Enrolling by invitation |
NCT02559453 -
Outcomes for 2 Operations Versus ≥ 3 Operations in Infected Wounds
|
N/A | |
Completed |
NCT02744144 -
Wound Bacterial Microbiota and Their Antibiotic Resistance
|
N/A | |
Active, not recruiting |
NCT01939145 -
Comparing Outcomes for Prontosan Versus Normal Saline for Negative Pressure Wound Therapy With Instillation
|
Phase 4 | |
Completed |
NCT00998907 -
PDS*Plus and Wound Infections After Laparotomy
|
N/A | |
Completed |
NCT01141335 -
Polypropylene Mesh Versus Polytetrafluoroethylene (PTFE) Mesh in Inguinal Hernia Repair
|
Phase 4 | |
Completed |
NCT00576745 -
A Comparison Of The 3M TM S Surgical Skin Closure System To The Standard Vicryl Suture Closure of Sternotomy Incisions During Cardiac Surgery
|
Phase 1 | |
Terminated |
NCT00654641 -
Prevention of Wound Complications After Cesarean Delivery in Obese Women Utilizing Negative Pressure Wound Therapy
|
N/A | |
Completed |
NCT00402727 -
Comparison of Sequential IV/PO Moxifloxacin With IV Piperacillin/Tazobactam Followed by PO Amoxicillin/Clavulanic Acid in Patients With a Complicated Skin and Skin Structure Infection
|
Phase 3 | |
Recruiting |
NCT00150852 -
Prevention of Gastrostomy-Related Wound Infection by Vancomycin in Carriers of Methicillin-Resistant Staphylococcus Aureus.
|
Phase 2 | |
Not yet recruiting |
NCT03872544 -
Short Term Status of Free Dermal Fat Autografts for Complex Craniofacial Wounds
|
||
Recruiting |
NCT04596124 -
Effectiveness and Tolerability of Fitostimoline Plus Cream and Gauze vs Connettivina Bio Plus Cream and Gauze
|
N/A | |
Active, not recruiting |
NCT04584957 -
Prophylactic Negative Pressure Wound Therapy (VAC) in Gynecologic Oncology (G.O.)
|
N/A | |
Enrolling by invitation |
NCT03880188 -
Long Term Status of Free Dermal Fat Autografts for Complex Craniofacial Wounds
|
||
Completed |
NCT02018094 -
The Amputation Surgical Site Infection Trial (ASSIT)
|
Phase 4 | |
Terminated |
NCT03269968 -
Use of Negative Pressure Wound Therapy in Morbidly Obese Women After Cesarean Delivery
|
N/A | |
Enrolling by invitation |
NCT02945761 -
High Concentration of Sugar Solution Irrigation Promotes the Healing of Infected Wound
|
N/A | |
Not yet recruiting |
NCT02882360 -
Kerlix for Pregnant Women With Elevated BMI to Prevent Wound Infection by 6 Weeks Post Partum
|
Phase 4 | |
Enrolling by invitation |
NCT01977989 -
Vancomycin in Spine Surgery
|
Phase 4 |